1104926-91-1

Basic information

• Product Name: 1,4-Dihydro-4-oxothieno[2,3-d]pyrimidine-5-carboxylic acid
• Synonyms: 1,4-Dihydro-4-oxothieno[2,3-d]pyrimidine-5-carboxylic acid;4-Oxo-1,4-dihydrothieno[2,3-d]pyrimidine-5-carboxylic acid
• CAS NO: 1104926-91-1
• Molecular Formula: C₇H₄N₂O₃S
• Molecular Weight: 196
• Mol File: 1104926-91-1.mol

Chemical Properties

• Appearance: /
• Density: 1.88
• CAS DataBase Reference: 1,4-Dihydro-4-oxothieno[2,3-d]pyrimidine-5-carboxylic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 1,4-Dihydro-4-oxothieno[2,3-d]pyrimidine-5-carboxylic acid(1104926-91-1)
• EPA Substance Registry System: 1,4-Dihydro-4-oxothieno[2,3-d]pyrimidine-5-carboxylic acid(1104926-91-1)

Safety Data

• Hazardous Substances Data: 1104926-91-1(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
1,4-Dihydro-4-oxothieno[2,3-d]pyrimidine-5-carboxylic acid is used as an antineoplastic agent for its potential to inhibit the growth of cancerous tumors. It is being studied for its properties that may contribute to the development of treatments for various types of cancer.
Additionally, it is used as a potential treatment for diabetes and other metabolic disorders, given its potential to address underlying biochemical imbalances and improve overall metabolic health.
Further research is ongoing to explore the full range of potential applications for 1,4-Dihydro-4-oxothieno[2,3-d]pyrimidine-5-carboxylic acid in the fields of medicine and pharmaceuticals, with the aim of expanding its use in therapeutic interventions.

Upstream product

• 844502-63-2 3-ethyl 4-methyl 2-aminothiophene-3,4-dicarboxylate 

Downstream Products

• 1456890-23-5 N-(4-carbamoylbenzyl)-4-oxo-3,4-dihydrothieno[2,3-d]pyrimidine-5-carboxamide 
• 1456890-24-6 N-(4-carbamimidoylbenzyl)-4-oxo-3,4-dihydrothieno[2,3-d]pyrimidine-5-carboxamide 

Relevant articles and documents

Selective inhibitors of bacterial t-RNA-(N1G37) methyltransferase (TrmD) that demonstrate novel ordering of the lid domain

The tRNA-(N1G37) methyltransferase (TrmD) is essential for growth and highly conserved in both Gram-positive and Gram-negative bacterial pathogens. Additionally, TrmD is very distinct from its human orthologue TRM5 and thus is a suitable target for the design of novel antibacterials. Screening of a collection of compound fragments using Haemophilus influenzae TrmD identified inhibitory, fused thieno-pyrimidones that were competitive with S-adenosylmethionine (SAM), the physiological methyl donor substrate. Guided by X-ray cocrystal structures, fragment 1 was elaborated into a nanomolar inhibitor of a broad range of Gram-negative TrmD isozymes. These compounds demonstrated no activity against representative human SAM utilizing enzymes, PRMT1 and SET7/9. This is the first report of selective, nanomolar inhibitors of TrmD with demonstrated ability to order the TrmD lid in the absence of tRNA.